GLP-1s offer significant promise to millions of Americans living with obesity, diabetes and/or cardiovascular disease, but their unprecedented demand and high price tags are creating challenging downstream impacts, including fluctuating supply, inconsistent clinical support, and runaway cost trajectory, said an Evernorth statement
Moyano D, Vilaseca MA, Artuch R, Lambruschini N
Significant negative symptoms were found in the active treatment group compared to controls but not in positive or general psychopathology [6]
Monitor INR when warfarin is co-administered with GLP-1 analogues
Weight loss is an important factor in type 2 diabetes management and is often complicated by diabetic agents that promote weight gain (i.e., sulfonylureas, thiazolidinediones (TZDs), insulin)